An Open-label Study in Healthy Male Subjects, to Determine the Excretion Balance and Pharmacokinetics of [14C]-GSK2269557, Administered as a Single Intravenous Microtracer (Concomitant With an Inhaled Non-radiolabelled Dose) and a Single Oral Dose
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs Nemiralisib (Primary) ; Nemiralisib (Primary)
- Indications Asthma; Bronchiectasis; Chronic obstructive pulmonary disease; Immunodeficiency disorders
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 24 Oct 2019 Results published in the Drug Metabolism and Disposition.
- 10 Jan 2018 Status changed from recruiting to completed.
- 27 Nov 2017 Status changed from not yet recruiting to recruiting.